Regeneron Pharmaceuticals Inc. (REGN)

321.39
NASDAQ : Health Technology
Prev Close 321.39
Day Low/High 0.00 / 0.00
52 Wk Low/High 313.53 / 543.55
Avg Volume 938.40K
Exchange NASDAQ
Shares Outstanding 105.78M
Market Cap 34.27B
EPS 11.30
P/E Ratio 31.20
Div & Yield N.A. (N.A)

Latest News

Regeneron Genetics Center® Publication In New England Journal Of Medicine Identifies New Genetic Variant Providing Protection From Chronic Liver Disease

Regeneron Genetics Center® Publication In New England Journal Of Medicine Identifies New Genetic Variant Providing Protection From Chronic Liver Disease

Findings validate importance of large-scale human genetics effort undertaken by Regeneron Genetics Center; provide target for potential development of new medicines

New Opportunities in Biotech: Cramer's 'Off the Charts'

New Opportunities in Biotech: Cramer's 'Off the Charts'

The beaten down biotech sector may offer more opportunities in this newly volatile market environment.

Chopping a Way Back for the Bull: Cramer's 'Mad Money' Recap (Tuesday 3/21/18)

Chopping a Way Back for the Bull: Cramer's 'Mad Money' Recap (Tuesday 3/21/18)

Jim Cramer maps out what investors need to find a way back to the upside, including the Fed, interest rates and earnings.

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Expect U.S. regulatory submission for diabetic retinopathy later this year

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Walt Disney Co., RH, Immunogen, and Advanced Micro Devices.

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

In the wake of Trump's blocking the Broadcom-Qualcomm deal, Jim Cramer ask if we should be worried that all of tech that wants to be big in China could be under pressure.

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Teen Scientists Win $1.8 Million At Regeneron Science Talent Search 2018 With Top Awards For Novel Research On Crop Blight, Vaping And Rare Disease

Top Projects at Nation's Oldest and Most Prestigious STEM Competition for High School Seniors Have Potential Implications for Agricultural Science, Public Health and Medical Diagnosis

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Jim Cramer looks at the investment strategies you need to use throughout your life, especially in a volatile market.

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Jim Cramer asks: Is every one of these vexing VIX derivatives going to have to go bust before this torture ends? Looks like it.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Forty Of The Nation's Most Promising Young Scientists Named Finalists In Regeneron Science Talent Search 2018

Finalists to Compete for More Than $1.8 Million in Oldest and Most Prestigious U.S. Science and Mathematics Competition for High School Seniors

Floor & Decor, Chegg, Core Labs, Cedar Fair: 'Mad Money' Lightning Round

Floor & Decor, Chegg, Core Labs, Cedar Fair: 'Mad Money' Lightning Round

Jim Cramer is bullish on Floor & Decor, Chegg, Core Labs, Cedar Fair, Newmark Group, First Solar.

Market's Animal Spirits Roar: Cramer's 'Mad Money' Recap (Thursday 1/11/18)

Market's Animal Spirits Roar: Cramer's 'Mad Money' Recap (Thursday 1/11/18)

Jim Cramer says this market's odd-couple behavior is worth investigating because it can push stocks even higher.

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

T-Mobile US, Take-Two Interactive, Owens Corning: 'Mad Money' Lightning Round

Jim Cramer highlights T-Mobile US, Take-Two Interactive, Activision Blizzard, Owens Corning and more.

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Investors, Here's Your Big Chance: Cramer's 'Mad Money' Recap (Thurs 12/14/17)

Weakness has been a clarion call to sell for so many, when it's really the buying opportunity that so few people recognize.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APEI, CMP, FRPT, GLP, OPHT, SEE, TA, TIS, VRTS Downgrades: BCRH, CAFD, KO, REGN, TERP Initiations: CRSP Read on to get TheStreet Quant Ratings' detailed report:

Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet

Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet

Traders and investors should stand aside until the situation with this biotech name offers a better entry point.

Investors Shun Biotech Stocks

Investors Shun Biotech Stocks

The speed at which investors have bailed on this sector is alarming.

TheStreet Quant Rating: C (Hold)